Printer Friendly

IMRE ANNOUNCES PUBLICATION IN NEW ENGLAND JOURNAL OF MEDICINE

 IMRE ANNOUNCES PUBLICATION IN NEW ENGLAND JOURNAL OF MEDICINE
 SEATTLE, Wash., March 12 /PRNewswire/ -- Imre Corporation (NASDAQ: IMRE) announced that the New England Journal of Medicine published data in its March 5, 1992 issue regarding the use of the company's Prosorba(R) column. The publication describes the experience of physicians treating a patient with thrombotic thrombocytopenic purpura (TTP), an immune blood clothing disorder with kidney malfunction. The patient had failed all conventional therapies, but responded to treatment with the company's product. In view of this report, the company is evaluating TTP as a disease in which the Prosorba(R) column may be useful.
 IMRE Corporation is a medical products company that is the leader in the field of immunoadsorption. The company's first product, the Prosorba(R) column, has been approved by the Food and Drug Administration for treatment of idiopathic thrombocytopenic purpura, an immune-related bleeding disorder. The company is currently conducting clinical trials in rheumatoid arthritis, other autoimmune diseases and certain cancers.
 -0- 3/12/92
 /CONTACT: Lois Yoshida of IMRE, 206-298-9400/
 (IMRE) CO: IMRE Corporation ST: Washington IN: MTC SU:


SM-OS -- NY014 -- 7673 03/12/92 09:47 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 12, 1992
Words:190
Previous Article:ICI EXPLOSIVES ANNOUNCES ACQUISITION OF FERTIMEX AMMONIUM NITRATE PLANT IN MEXICO
Next Article:THE WASHINGTON POST COMPANY DECLARES REGULAR QUARTERLY DIVIDEND
Topics:


Related Articles
THE JOURNAL TRANSFUSION PUBLISHES ARTICLE ON TREATMENT OF REFRACTORINESS TO PLATELET TRANSFUSION WITH IMRE CORPORATION'S PROSORBA COLUMN
JOURNAL OF CLINICAL APHERESIS PUBLISHES RESULTS OF TREATMENT OF NERVOUS DISEASE WITH IMRE CORPORATION'S PROSORBA COLUMN
IMRE AND BAXTER SIGN DISTRIBUTION AGREEMENT
PAUL SELF RESIGNS AS PRESIDENT AND CHIEF OPERATING OFFICER OF IMRE CORPORATION
HARVEY J. HOYT, M.D., TO ASSUME ADDITIONAL RESPONSIBILITIES AT IMRE
IMRE CORPORATION'S PROSORBA(R) COLUMN SHOWN BENEFICIAL IN TREATING NEUROLOGICAL CONDITIONS
IMRE CORPORATION BEGINS KIDNEY TRANSPLANTATION CLINICAL TRIAL
IMRE CORPORATION PRESENTS A METHOD TO TREAT BLEEDING DISORDERS
IMRE CORPORATION ANNOUNCES POSITIVE RHEUMATOID ARTHRITIS CLINICAL TRIAL RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters